Targeting Cutaneous Cannabinoid Signaling in Inflammation: A Highway to Heal?

The document explored the endocannabinoid system's (ECS) role in skin inflammation and homeostasis, emphasizing the importance of ECS components like CB1 and CB2 receptors and the enzyme FAAH in managing skin inflammatory processes. Mouse model studies demonstrated that disrupting cannabinoid signaling increased skin inflammation, whereas enhancing ECS activity reduced it. The research suggested that FAAH inhibitors and non-psychotropic phytocannabinoids, such as cannabidiol (CBD), showed potential as treatments for skin conditions like acne and atopic dermatitis due to their anti-inflammatory effects, indicating that targeting ECS could provide new therapeutic strategies for skin inflammation management.